Baloxavir Marboxil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 320 publications
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2025.
Journal: Communicable diseases intelligence (2018)
Published: August 25, 2026
The global demand and potential public health impact of oral antiviral treatment stockpile for influenza pandemics.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 28, 2026
Parameterization of the PA Endonuclease Bimetallic Center Reveals the Dynamics of Clinically Relevant Mutations.
Journal: Journal of chemical theory and computation
Published: July 27, 2026
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
Journal: Emerging microbes & infections
Published: July 10, 2026
Analytical Techniques for Baloxavir Marboxil: A Critical Review of Chromatographic, Mass Spectrometric, and Emerging Methods (2018-2025).
Journal: Critical reviews in analytical chemistry
Published: June 23, 2026
Baloxavir marboxil-related information on Douyin and Xiaohongshu: a cross-sectional analysis of content, misinformation, and user engagement.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: May 25, 2026
Efficacy and safety of baloxavir marboxil vs. oseltamivir in Chinese outpatients with influenza B: an IPTW-adjusted real-world cohort study.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 30, 2026
Identification of related substances in baloxavir marboxil using 2D-LC-Q-TOF/MS.
Journal: Journal of pharmaceutical and biomedical analysis
Published: April 24, 2026
Antiviral activities of multiple antivirals against highly pathogenic avian influenza A H5N1 in vitro and in mice.
Journal: Emerging microbes & infections
Published: March 31, 2026
Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: March 05, 2026
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2024.
Journal: Communicable diseases intelligence (2018)
Published: February 23, 2026
Last Updated: 09/26/2026